142 related articles for article (PubMed ID: 26210384)
1. Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.
Koh MS; Kim WS; Kim SJ; Oh SY; Yoon DH; Lee SI; Hong J; Song MK; Shin HJ; Kwon JH; Kim HJ; Do YR; Suh C; Kim HJ
Int J Hematol; 2015 Oct; 102(4):420-5. PubMed ID: 26210384
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Kwon HC; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Lee GW; Choi CW; Park J; Suh C; Kim HJ
Ann Hematol; 2010 Jun; 89(6):563-8. PubMed ID: 20024551
[TBL] [Abstract][Full Text] [Related]
3. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease.
Oh SY; Kwon HC; Kim WS; Hwang IG; Park YH; Kim K; Ko YH; Ryoo BY; Kang HJ; Nam E; Lee JH; Kim JH; Kim HJ
Eur J Haematol; 2007 Oct; 79(4):287-91. PubMed ID: 17692101
[TBL] [Abstract][Full Text] [Related]
4. Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL).
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Lee SI; Kang HJ; Choi CW; Park J; Song MK; Kim HJ; Kwon JH; Kwak JY; Bae SH; Park BB; Do YR; Lee HS; Jeong SH; Suh C; Kim HJ
Int J Hematol; 2012 Nov; 96(5):631-7. PubMed ID: 23065471
[TBL] [Abstract][Full Text] [Related]
5. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
[TBL] [Abstract][Full Text] [Related]
6. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.
Oh SY; Ryoo BY; Kim WS; Park YH; Kim K; Kim HJ; Kwon JM; Lee J; Ko YH; Ahn YC; Oh SJ; Lee SI; Kim HJ; Kwon HC; Bang SM; Kim JH; Park J; Lee SS; Kim HY; Park K
Am J Hematol; 2007 Jun; 82(6):446-52. PubMed ID: 17266060
[TBL] [Abstract][Full Text] [Related]
7. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.
Oh SY; Ryoo BY; Kim WS; Kim K; Lee J; Kim HJ; Kwon JM; Lee HR; Ko YH; Oh SJ; Park KW; Kim HJ; Kwon HC; Nam E; Kim JH; Park YH; Lee SS; Kim HY; Park K
Ann Hematol; 2006 Nov; 85(11):781-6. PubMed ID: 16847665
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
Oh SY; Kim WS; Lee DH; Kim SJ; Kim SH; Ryoo BY; Kang HJ; Choi YJ; Chung JS; Kim HJ; Suh C
Invest New Drugs; 2010 Apr; 28(2):171-7. PubMed ID: 19421710
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
[TBL] [Abstract][Full Text] [Related]
10. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites.
Kuper-Hommel MJ; van de Schans SA; Vreugdenhil G; van Krieken JH; Coebergh JW
Leuk Lymphoma; 2013 Sep; 54(9):1891-7. PubMed ID: 23302044
[TBL] [Abstract][Full Text] [Related]
11. Primary thyroid marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: clinical manifestation and outcome of a rare disease - consortium for improving survival of lymphoma study.
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Kang HJ; Song MK; Kim HJ; Kwon JH; Kwak JY; Park BB; Do YR; Jeong SH; Suh C
Acta Haematol; 2012; 127(2):100-4. PubMed ID: 22178776
[TBL] [Abstract][Full Text] [Related]
12. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
13. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study.
Oh SY; Kwon HC; Kim WS; Park YH; Kim K; Kim HJ; Kwon JM; Lee J; Ko YH; Ahn YC; Oh SJ; Lee SI; Bang SM; Kim JH; Park J; Ryoo BY; Lee SS; Kim HY; Park K; Kim HJ
Cancer Lett; 2007 Dec; 258(1):90-7. PubMed ID: 17936499
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
Kang HJ; Kim WS; Kim SJ; Lee JJ; Yang DH; Kim JS; Lee SR; Lee GW; Kim HJ; Kim HY; Oh SY; Kim HC; Eom HS; Chung J; Park J; Suh C; Ryoo BY
Ann Hematol; 2012 Apr; 91(4):543-51. PubMed ID: 21922208
[TBL] [Abstract][Full Text] [Related]
15. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).
Jackson AE; Mian M; Kalpadakis C; Pangalis GA; Stathis A; Porro E; Conconi A; Cortelazzo S; Gaidano G; Lopez Guillermo A; Johnson PW; Martelli M; Martinelli G; Thieblemont C; McPhail ED; Copie-Bergman C; Pileri SA; Jack A; Campo E; Mazzucchelli L; Ristow K; Habermann TM; Cavalli F; Nowakowski GS; Zucca E
Oncologist; 2015 Oct; 20(10):1149-53. PubMed ID: 26268740
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma.
Teckie S; Qi S; Chelius M; Lovie S; Hsu M; Noy A; Portlock C; Yahalom J
Ann Oncol; 2017 May; 28(5):1064-1069. PubMed ID: 28327924
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent.
Teckie S; Qi S; Lovie S; Navarrett S; Hsu M; Noy A; Portlock C; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):130-7. PubMed ID: 25863760
[TBL] [Abstract][Full Text] [Related]
18. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
19. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases.
Oh SY; Kim WS; Kim SJ; Kim JS; Kim SH; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Kim JG; Yang DH; Kang HJ; Choi CW; Park J; Choi YJ; Kim HJ; Kwon JH; Suh C; Kim HJ
Am J Hematol; 2009 Dec; 84(12):826-9. PubMed ID: 19890833
[TBL] [Abstract][Full Text] [Related]
20. Role of surgery in the patients with stage I and II primary gastric lymphoma.
Takahashi I; Maehara Y; Koga T; Sumiyoshi Y; Oshiro T; Baba H; Kohnoe S; Okamura T; Uike N; Matsusaka T; Kume K; Sugimachi K
Hepatogastroenterology; 2003; 50(51):877-82. PubMed ID: 12828109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]